ClawHub

Exelixis

v1.0.0

Exelixis develops cabozantinib-based multi-kinase inhibitors for kidney, liver, and thyroid cancers, focusing on oncology combination therapies and pipeline...

⭐ 0· 65·0 current·0 all-time
by@hanxueyuan

Install

OpenClaw Prompt Flow

Install with OpenClaw

Best for remote or guided setup. Copy the exact prompt, then paste it into OpenClaw for hanxueyuan/exelixis.

Previewing Install & Setup.
Prompt PreviewInstall & Setup
Install the skill "Exelixis" (hanxueyuan/exelixis) from ClawHub.
Skill page: https://clawhub.ai/hanxueyuan/exelixis
Keep the work scoped to this skill only.
After install, inspect the skill metadata and help me finish setup.
Use only the metadata you can verify from ClawHub; do not invent missing requirements.
Ask before making any broader environment changes.

Command Line

CLI Commands

Use the direct CLI path if you want to install manually and keep every step visible.

OpenClaw CLI

Bare skill slug

openclaw skills install exelixis

ClawHub CLI

Package manager switcher

npx clawhub@latest install exelixis
Security Scan
VirusTotalVirusTotal
Benign
View report →
OpenClawOpenClaw
Benign
high confidence
✓
Purpose & Capability
The skill's name and description match the SKILL.md content (company background, timeline, business analysis). It does not request unrelated resources or capabilities. Note: the skill's source/homepage is unknown, which limits verifiability but does not create an internal coherence problem.
✓
Instruction Scope
SKILL.md contains only static informational content and 'read_when' guidance for when to use it. It does not instruct the agent to read system files, access environment variables, or send data externally.
✓
Install Mechanism
No install spec and no code files — instruction-only. There is nothing written to disk or downloaded during install.
✓
Credentials
The skill declares no required environment variables, credentials, or config paths; requested privileges are minimal and proportional to an informational skill.
✓
Persistence & Privilege
always is false and the skill does not request persistent presence or modify other skills. disable-model-invocation is false (normal); autonomous invocation is allowed by platform default but this skill's read-only nature keeps risk low.
Assessment
This skill is informational only and does not request credentials or install software, so it appears safe to add from a system-privilege perspective. However, the skill's source/homepage is unknown and SKILL.md is a static summary — verify any clinical, financial, or regulatory claims against authoritative sources (company filings, peer-reviewed literature, FDA notices) before using the information for decisions, and do not treat it as medical advice.

Like a lobster shell, security has layers — review code before you run it.

latestvk973qa41qz9myhjqt7674yt3w985g89r
65downloads
0stars
1versions
Updated 2d ago
v1.0.0
MIT-0
@hanxueyuan
latest
Download

Exelixis

历史时间线

  • 1994: Founded in Alameda, California
  • 2000s: Pioneers small-molecule kinase inhibitor discovery platform
  • 2012: FDA approves cabozantinib (Cometriq) for medullary thyroid cancer
  • 2016: Cabometyx approved for advanced renal cell carcinoma
  • 2019: HCC indication approved (liver cancer)
  • 2021: COSMIC-313 trial shows combination therapy benefit
  • 2023: Revenue $2.2B, expanding into new oncology indications
  • 2024: Pipeline expansion beyond cabozantinib

商业模式

Focused oncology company centered on cabozantinib (Cabometyx), a multi-kinase inhibitor targeting MET, VEGFR2, and AXL. Revenue from Cabometyx sales across kidney cancer, liver cancer, and thyroid cancer. Pipeline includes next-generation kinase inhibitors and combination therapies with immunotherapy.

护城河分析

Cabozantinib's multi-kinase targeting creates broader efficacy than single-target competitors. Expanded label across three cancer types diversifies revenue. Long patent life with potential extensions through combination indications.

关键数据

  • Founded: 1994, Alameda, California
  • Revenue 2023: ~$2.2B
  • Employees: ~800
  • Flagship Drug: Cabometyx (cabozantinib)
  • Indications: Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer

有趣事实

  • Exelixis's name comes from 'helix' (DNA) and the Greek prefix for 'evolution' — reflecting their focus on evolving cancer treatments.
  • Cabozantinib was originally developed for thyroid cancer but found its biggest commercial success in kidney and liver cancer — a classic example of drug repurposing.

Comments

Loading comments...